Increased levels of tumour necrosis factor-α (TNF-α) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction

Clinical Science

Volumn 110, Issue 6, 2006, Pages 673-681

  Nyström, Thomas ^a   Nygren, Arne ^a   Sjöholm, Åke ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Adiponectin; Endothelial dysfunction; Inflammation; Interleukin 6; Resistin; Tumour necrosis factor (TNF ); Type II diabetes

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; GLYCERYL TRINITRATE; INTERLEUKIN 6; LIPID; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; VASODILATATION;

ADIPONECTIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33744917283     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050353     Document Type: Article

References (41)

1. Haffner, S. M., Lehto, S., Ronnemaa, T. et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234
2. Sjöholm, A. and Nyström, T. (2005) Endothelial inflammation in insulin resistance. Lancet 365, 610-612
3. Ross, R. (1999) Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340, 115-126
4. Vita, J. A. and Keaney, Jr, J. F. (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106, 640-642
5. Suwaidi, J. A., Hamasaki, S., Higano, S. T. et al. (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101, 948-954
6. Moreno, P. R. and Fuster, V. (2004) New aspects in the pathogenesis of diabetic atherothrombosis. J. Am. Coll. Cardiol. 44, 2293-2300
7. Caballero, A. E. (2004) Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr. Diabetes Rep. 4, 237-246
8. The Joint European Society of Cardiology/American College of Cardiology Committee (2000) Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur. Heart. J. 21, 1502-1513
9. Celermajer, D. S., Sorensen, K. E., Gooch, V. M. et al. (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340, 1111-1115
10. Nyström, T., Nygren, A. and Sjöholm, A. (2004) Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. Am. J. Physiol. Endocrinol. Metab. 287, E919-E925
11. DeFronzo, R. A., Tobin, J. D. and Andres, R. (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214-E223
12. Grundy, S. M., Brewer, Jr, H. B., Cleeman, J. I. et al. (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433-438
13. Calles-Escandon, J. and Cipolla, M. (2001) Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 22, 36-52
14. Silber, H. A., Ouyang, P., Bluemke, D. A. et al. (2004) Why is flow mediated dilation dependent on arterial size? assessment of the shear stimulus using phase contrast magnetic resonance imaging. Am. J. Physiol. Heart. Circ. Physiol. 288, H822-H828
15. Xu, H., Barnes, G. T., Yang, Q. et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830
16. Kern, P. A., Saghizadeh, M., Ong, J. M. et al. (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95, 2111-2119
17. Burger, D. and Dayer, J. M. (2002) Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-α production in contact-mediated activation of monocytes by T lymphocytes. Ann. N.Y. Acad. Sci. 966, 464-473
18. Aoki, N., Siegfried, M. and Lefer, A. M. (1989) Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries. Am. J. Physiol. 256, H1509-H1512
19. Bhagat, K. and Vallance, P. (1997) Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 96, 3042-3047
20. Kim, F., Gallis, B. and Corson, M. A. (2001) TNF-α inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am. J. Physiol. Cell. Physiol. 280, C1057-C1065
21. Hotamisligil, G. S., Budavari, A., Murray, D. and Spiegelman, B. M. (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α. J. Clin. Invest. 94, 1543-1549
22. Rask-Madsen, C., Dominguez, H., Ihlemann, N. et al. (2003) Tumor necrosis factor-α inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108, 1815-1821
23. Hurlimann, D., Forster, A., Noll, G. et al. (2002) Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187
24. Bilsborough, W., O'Driscoll, G., Stanton, K. et al. (2002) Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in Type II diabetes. Clin. Sci. 103, 163-169
25. Nyström, T., Nygren, A. and Sjöholm, A. (2005) Persistent endothelial dysfunction is related to elevated CRP levels in Type II diabetic patients after acute myocardial infarction. Clin. Sci. 108, 121-128
26. Verma, S., Wang, C. H., Lonn, E. et al. (2004) Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals. Eur. Heart J. 25, 1754-1760
27. Vita, J. A., Keaney, Jr, J. F., Larson, M. G. et al. (2004) Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation 110, 3604-3609
28. Szmitko, P. E., Wang, C. H., Weisel, R. D. et al. (2003) New markers of inflammation and endothelial cell activation: Part I. Circulation 108, 1917-1923
29. Szmitko, P. E., Wang, C. H., Weisel, R. D. et al. (2003) Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 108, 2041-2048
30. Adams, M. R., Robinson, J., McCredie, R. et al. (1998) Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J. Am. Coll. Cardiol. 32, 123-127
31. Zeng, G. and Quon, M. J. (1996) Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest. 98, 894-898
32. Steinberg, H. O., Chaker, H., Leaming, R. et al. (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97, 2601-2610
33. Scherrer, U., Randin, D., Vollenweider, P. et al. (1994) Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. Invest. 94, 2511-2515
34. Ritchie, S. A., Ewart, M. A., Perry, C. G. et al. (2004) The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin. Sci. 107, 519-532
35. Wendelhag, I., Fagerberg, B., Hulthe, J. et al. (2002) Endothelium-dependent flow-mediated vasodilatation, insulin resistance and the metabolic syndrome in 60-year-old men. J. Intern. Med. 252, 305-313
36. Pickup, J. C. (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27, 813-823
37. Fernandez-Real, J. M., Castro, A., Vazquez, G. et al. (2004) Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 27, 739-745
38. Shetty, G. K., Economides, P. A., Horton, E. S. et al. (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27, 2450-2457
39. Chandran, M., Phillips, S. A., Ciaraldi, T. and Henry, R. R. (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26, 2442-2450
40. Krakoff, J., Funahashi, T., Stehouwer, C. D. et al. (2003) Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26, 1745-1751
41. Yokota, T., Oritani, K., Takahashi, I. et al. (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96, 1723-1732